Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group.

JAMA Netw Open. 2019 Sep 4;2(9):e1911750. doi: 10.1001/jamanetworkopen.2019.11750.

2.

Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings.

Bonadio RC, Amor Divino PH, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PM.

J Glob Oncol. 2019 Sep;5:1-6. doi: 10.1200/JGO.19.00180.

3.

Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.

Victor CR, Fujiki FK, Takeda FR, Hoff PMG, de Castria TB.

J Glob Oncol. 2019 Jul;5:1-10. doi: 10.1200/JGO.19.00103.

4.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PM, Shah MA, Shen L, Kang YK, Alsina M, Girish S, Garg A.

Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.

5.

Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.

Riechelmann RP, Leite LS, Bariani GM, Glasberg J, Rivelli TG, da Fonseca LG, Nebuloni DR, Braghiroli MI, Queiroz MA, Isejima AM, Kappeler C, Kikuchi L, Hoff PM.

Oncologist. 2019 Sep;24(9):1180-1187. doi: 10.1634/theoncologist.2019-0067. Epub 2019 Jun 7.

PMID:
31175167
6.

Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer.

Sales ARK, Negrão MV, Testa L, Ferreira-Santos L, Groehs RVR, Carvalho B, Toschi-Dias E, Rocha NG, Laurindo FRM, Debbas V, Rondon MUPB, Mano MS, Hajjar LA, Hoff PMG, Filho RK, Negrão CE.

Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(7):H1-H12. doi: 10.1152/ajpheart.00756.2018. Epub 2019 Apr 19.

PMID:
31002284
7.

Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center.

Silva ACB, Vicentini MFB, Mendoza EZ, Fujiki FK, da Fonseca LG, Braghiroli MIFM, Hoff PM.

Curr Probl Cancer. 2019 Feb 20. pii: S0147-0272(18)30204-6. doi: 10.1016/j.currproblcancer.2019.01.009. [Epub ahead of print]

PMID:
30826126
8.

ICESP, a research hub within a total cancer care center.

Chammas R, Fernandes JC, Hoff PMG.

Clinics (Sao Paulo). 2019 Feb 4;74:e113. doi: 10.6061/clinics/2019/e1113. No abstract available.

9.

Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.

Mota JM, Sousa LG, Braghiroli MI, Siqueira LT, Neto JEB, Chapchap P, Hoff AAO, Hoff PM.

Medicine (Baltimore). 2018 Dec;97(52):e13517. doi: 10.1097/MD.0000000000013517.

10.

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.

da Fonseca LG, Marta GN, Braghiroli MIFM, Chagas AL, Carrilho FJ, Hoff PM, Sabbaga J.

BMC Cancer. 2018 Dec 13;18(1):1250. doi: 10.1186/s12885-018-5173-0.

11.

Return to work after breast cancer diagnosis: An observational prospective study in Brazil.

Landeiro LCG, Gagliato DM, Fêde AB, Fraile NM, Lopez RM, da Fonseca LG, Petry V, Testa L, Hoff PM, Mano MS.

Cancer. 2018 Dec 15;124(24):4700-4710. doi: 10.1002/cncr.31735. Epub 2018 Oct 17.

PMID:
30329152
12.

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK.

Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.

PMID:
30217672
13.

Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

Girardi DM, Faria LDBB, Teixeira MC, Costa FP, Hoff PMG, Fernandes GS.

J Gastrointest Cancer. 2018 Sep 3. doi: 10.1007/s12029-018-0166-4. [Epub ahead of print]

PMID:
30175393
14.

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy.

Arai RJ, Petry V, Hoff PM, Mano MS.

Biomark Res. 2018 Jun 14;6:20. doi: 10.1186/s40364-018-0135-x. eCollection 2018.

15.

Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1.

Caires-Lima R, Cayres K, Protásio B, Caires I, Andrade J, Rocha L, Takahashi TK, Hoff PM, de Castro G Jr, Mak MP.

Ecancermedicalscience. 2018 Apr 30;12:831. doi: 10.3332/ecancer.2018.831. eCollection 2018.

16.

Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis.

Girardi DM, de Lima MA, Pereira GCB, Negrão MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG.

BMC Cancer. 2018 Apr 3;18(1):378. doi: 10.1186/s12885-018-4305-x.

17.

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA.

J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11.

18.

Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer.

Braghiroli MI, Mota JM, Duarte PS, Morita TO, Bariani GM, Nebuloni D, Buchpiguel CA, Hoff PM, Riechelmann RP.

Nucl Med Commun. 2018 Mar;39(3):252-259. doi: 10.1097/MNM.0000000000000810.

PMID:
29381586
19.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
20.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

21.

Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.

Ramos REO, Perez Mak M, Alves MFS, Piotto GHM, Takahashi TK, Gomes da Fonseca L, Silvino MCM, Hoff PM, de Castro G Jr.

J Glob Oncol. 2017 Dec;3(6):728-733. doi: 10.1200/JGO.2016.006890. Epub 2017 Mar 15.

22.

TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias.

Asprino PF, Linck RDM, Cesar J, Freitas FP, Koyama FC, Riechelmann RSP, Costa FP, Hoff PMG, Galante PAF, Meyer D, Camargo AA, Sabbaga J.

Endocr Relat Cancer. 2018 Feb;25(2):L1-L5. doi: 10.1530/ERC-17-0286. Epub 2017 Nov 22. No abstract available.

23.

Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?

Fernandes GS, Marques DF, Girardi DM, Braghiroli MIF, Coudry RA, Meireles SI, Katz A, Hoff PM.

Clinics (Sao Paulo). 2017 Oct;72(10):588-594. doi: 10.6061/clinics/2017(10)01.

24.

Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.

de M Rêgo JF, de Medeiros RSS, Braghiroli MI, Galvão B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP.

Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.

25.

Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.

Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi DDM, Braghiroli OFM, Costa FP, Hoff PM.

J Gastrointest Cancer. 2018 Dec;49(4):470-475. doi: 10.1007/s12029-017-0001-3.

PMID:
28884286
26.

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Xavier FD, Hoff PMG, Braghiroli MI, Paterlini ACCR, Souza KT, Faria LDBB, Ferreira FSB, Machado KK, Fernandes GDS.

J Glob Oncol. 2016 Jun 22;3(1):15-22. doi: 10.1200/JGO.2015.002527. eCollection 2017 Feb.

27.

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.

de Andrade DC, Jacobsen Teixeira M, Galhardoni R, Ferreira KSL, Braz Mileno P, Scisci N, Zandonai A, Teixeira WGJ, Saragiotto DF, Silva V, Raicher I, Cury RG, Macarenco R, Otto Heise C, Wilson Iervolino Brotto M, Andrade de Mello A, Zini Megale M, Henrique Curti Dourado L, Mendes Bahia L, Lilian Rodrigues A, Parravano D, Tizue Fukushima J, Lefaucheur JP, Bouhassira D, Sobroza E, Riechelmann RP, Hoff PM; PreOx Workgroup, Valério da Silva F, Chile T, Dale CS, Nebuloni D, Senna L, Brentani H, Pagano RL, de Souza ÂM.

Oncologist. 2017 Oct;22(10):1154-e105. doi: 10.1634/theoncologist.2017-0235. Epub 2017 Jun 26.

28.
29.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

30.

The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment.

Connell LC, Mota JM, Braghiroli MI, Hoff PM.

Curr Treat Options Oncol. 2017 Apr;18(4):23. doi: 10.1007/s11864-017-0463-3. Review.

PMID:
28391421
31.

Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group.

Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK.

Ecancermedicalscience. 2017 Jan 26;11:716. doi: 10.3332/ecancer.2017.716. eCollection 2017.

32.

Integrated care pathway for rectal cancer treatment: health care resource utilization, costs, and outcomes.

Kobayashi ST, Diz MDPE, Campolina AG, De Soárez PC, Ribeiro U Jr, Nahas SC, Vasconcelos KGMC, Capareli F, Cecconello I, Hoff PM.

Int J Evid Based Healthc. 2017 Jun;15(2):53-62. doi: 10.1097/XEB.0000000000000099.

PMID:
28157723
33.

Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis.

Souza KT, Pereira AA, Araujo RL, Oliveira SC, Hoff PM, Riechelmann RP.

Ecancermedicalscience. 2016 Dec 1;10:699. doi: 10.3332/ecancer.2016.699. eCollection 2016.

34.

Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.

Alex AK, Siqueira S, Coudry R, Santos J, Alves M, Hoff PM, Riechelmann RP.

Clin Colorectal Cancer. 2017 Sep;16(3):228-239. doi: 10.1016/j.clcc.2016.11.001. Epub 2016 Nov 26.

PMID:
28063788
35.

Pathology of Anal Cancer.

Hoff PM, Coudry R, Moniz CM.

Surg Oncol Clin N Am. 2017 Jan;26(1):57-71. doi: 10.1016/j.soc.2016.07.013. Review.

PMID:
27889037
36.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.

Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB.

JAMA Oncol. 2017 Jun 1;3(6):767-773. doi: 10.1001/jamaoncol.2016.3358. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742.

37.

Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma.

Mota JM, Scaranti M, Fonseca LG, Tolói DA, de Camargo VP, Munhoz RR, Feher O, Hoff PM.

Case Rep Oncol. 2016 Aug 24;9(2):481-487. eCollection 2016 May-Aug.

38.

Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.

Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff PM.

Clin Colorectal Cancer. 2017 Mar;16(1):65-72. doi: 10.1016/j.clcc.2016.07.001. Epub 2016 Jul 19.

PMID:
27515842
39.

Review on TAS-102 development and its use for metastatic colorectal cancer.

Mota JM, Fonseca LG, Braghiroli MI, Hoff PM.

Crit Rev Oncol Hematol. 2016 Aug;104:91-7. doi: 10.1016/j.critrevonc.2016.05.015. Epub 2016 May 26. Review.

PMID:
27296058
40.

Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer.

Miranda VC, Braghiroli MI, Faria LD, Bariani G, Alex A, Bezerra Neto JE, Capareli FC, Sabbaga J, Lobo Dos Santos JF, Hoff PM, Riechelmann RP.

Clin Colorectal Cancer. 2016 Dec;15(4):321-328.e1. doi: 10.1016/j.clcc.2016.04.011. Epub 2016 May 7.

PMID:
27262895
41.

Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.

Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, Ribeiro U Jr, Cotti GC, Imperiale AR, Capareli FC, Chih Chen AT, Hoff PM, Cecconello I.

Dis Colon Rectum. 2016 Apr;59(4):255-63. doi: 10.1097/DCR.0000000000000558.

PMID:
26953983
42.

High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.

Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A.

Clin Colorectal Cancer. 2016 Jun;15(2):e1-7. doi: 10.1016/j.clcc.2015.12.007. Epub 2015 Dec 29.

43.

Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia.

Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri ASG, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, Rossi F, Hajjar L, Levin AS, Hoff PM, Pierrotti LC, Abdala E.

Clin Microbiol Infect. 2016 Apr;22(4):352-358. doi: 10.1016/j.cmi.2015.12.010. Epub 2015 Dec 19.

44.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J.

Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9.

PMID:
26706237
45.

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.

de Castroneves LA, Negrão MV, de Freitas RM, Papadia C, Lima JV Jr, Fukushima JT, Simão EF, Kulcsar MA, Tavares MR, Jorge AA, de Castro G Jr, Hoff PM, Hoff AO.

Thyroid. 2016 Mar;26(3):414-9. doi: 10.1089/thy.2015.0334. Epub 2016 Feb 9.

PMID:
26701095
46.

Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.

Oliveira SC, Moniz CM, Riechelmann R, Alex AK, Braghirolli MI, Bariani G, Nahas C, Hoff PM.

J Gastrointest Cancer. 2016 Mar;47(1):75-81. doi: 10.1007/s12029-015-9790-4.

PMID:
26691173
47.

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D.

J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30.

PMID:
26628478
48.

Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer.

Garcia GH, Riechelmann RP, Hoff PM.

Clinics (Sao Paulo). 2015 Oct;70(10):696-9. doi: 10.6061/clinics/2015(10)07.

49.

Acquired hemophilia A in a patient with advanced prostate cancer.

Girardi Dda M, Silva DR, Villaça PR, Souza CE, da Fonseca LG, Bastos DA, Hoff PM.

Autops Case Rep. 2015 Jun 30;5(2):55-9. doi: 10.4322/acr.2015.008. eCollection 2015 Apr-Jun.

50.

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.

Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, Reis LF, Galante PA, Camargo AA.

Oncotarget. 2015 Oct 27;6(33):34221-7. doi: 10.18632/oncotarget.5950.

Supplemental Content

Support Center